US-based therapeutics device company Clarimedix secured an undisclosed amount of funding on Wednesday from the Johnson & Johnson Corporate Office of Science and Technology (COSAT), part of the pharmaceutical conglomerate’s website where innovators submit ideas to Johnson & Johnson operating companies..

Clarimedix focuses its research on disorders associated with blood vessel problems, Alzheimer’s disease among them. The technology used by Clarimedix involves a ligh-emitting diode (LED) patch that can be placed on the skin to trigger nitric oxide production in the body, increasing blood flow and reducing inflammation.

John Dunning, chief executive officer of Clarimedix, said: "We’re delighted to have the investment from the Johnson & Johnson COSAT as we secure validation of Clarimedix’s proprietary technology. Researchers understand there are a wide variety of conditions impacted by underlying vascular dysfunction and our approach may offer the first safe, effective nitric oxide (NO) treatment for patients with these hard-to-treat conditions." 

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?